Moment of truth looms for Nektar, Bristol-Myers with a major update to NKTR-214 combo — and the latest snapshot is not promising
Just 8 months after Bristol-Myers paid Nektar $1.85 billion in cash upfront to ally themselves on NKTR-214, an IL-2 drug that uses pegylation tech to try to overcome the severe limitations that hamper the first-gen approaches, researchers are scheduled to add on a significant update to their proof-of-concept Phase I/II study.
On Tuesday, investigators got a peek at some new numbers when Nektar filed a short-term, 6-week update in an abstract for SITC adding 10 patients to the mix receiving a combination of Opdivo and NKTR-214 for first-line melanoma. They counted an extra 5 objective responses among the 38 — which keeps the ORR response rate right at half.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.